GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (NAS:CSCI) » Definitions » Cyclically Adjusted Price-to-FCF

CSCI (Cosciens Biopharma) Cyclically Adjusted Price-to-FCF : (As of Jun. 03, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cosciens Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cosciens Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Cyclically Adjusted Price-to-FCF Chart

Cosciens Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 792.51 - -

Cosciens Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cosciens Biopharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cosciens Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

Cosciens Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cosciens Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cosciens Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.793/129.1809*129.1809
=-0.793

Current CPI (Mar. 2025) = 129.1809.

Cosciens Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.139 100.500 -0.179
201509 -0.038 100.421 -0.049
201512 0.395 99.947 0.511
201603 0.355 101.054 0.454
201606 -0.470 102.002 -0.595
201609 0.027 101.765 0.034
201612 0.036 101.449 0.046
201703 -0.572 102.634 -0.720
201706 -0.451 103.029 -0.565
201709 0.226 103.345 0.283
201712 -0.280 103.345 -0.350
201803 0.017 105.004 0.021
201806 -0.171 105.557 -0.209
201809 -0.436 105.636 -0.533
201812 -0.782 105.399 -0.958
201903 0.123 106.979 0.149
201906 0.200 107.690 0.240
201909 0.084 107.611 0.101
201912 -0.178 107.769 -0.213
202003 0.196 107.927 0.235
202006 0.854 108.401 1.018
202009 0.792 108.164 0.946
202012 -0.213 108.559 -0.253
202103 0.014 110.298 0.016
202106 0.907 111.720 1.049
202109 0.060 112.905 0.069
202112 0.204 113.774 0.232
202203 0.485 117.646 0.533
202206 1.074 120.806 1.148
202209 0.539 120.648 0.577
202212 0.558 120.964 0.596
202303 -0.466 122.702 -0.491
202306 -0.469 124.203 -0.488
202309 0.051 125.230 0.053
202312 -0.905 125.072 -0.935
202403 -1.593 126.258 -1.630
202406 -0.696 127.522 -0.705
202409 -2.546 127.285 -2.584
202412 -1.054 127.364 -1.069
202503 -0.793 129.181 -0.793

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cosciens Biopharma  (NAS:CSCI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cosciens Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Industry
Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.